Aug 11 (Reuters) - IO Biotech ( IOBT ) said on Monday

its experimental cancer vaccine, in combination with Merck's ( MRK )

Keytruda, showed improvement in a late-stage study goal,

but was not statistically significant.

It was testing the vaccine in 407 patients with advanced

skin cancer.

The company said it plans to meet with the U.S. Food and

Drug Administration this fall to discuss the data and next steps

for a potential regulatory submission.